153 related articles for article (PubMed ID: 9287139)
1. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo.
Maruyama K; Takahashi N; Tagawa T; Nagaike K; Iwatsuru M
FEBS Lett; 1997 Aug; 413(1):177-80. PubMed ID: 9287139
[TBL] [Abstract][Full Text] [Related]
2. PEG-immunoliposome.
Maruyama K
Biosci Rep; 2002 Apr; 22(2):251-66. PubMed ID: 12428903
[TBL] [Abstract][Full Text] [Related]
3. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
4. Improvement of therapeutic effect by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes.
Uyama I; Kumai K; Yasuda T; Tagawa T; Ishibiki K; Kitajima M; Tadakuma T
Jpn J Cancer Res; 1994 Apr; 85(4):434-40. PubMed ID: 8200855
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting by liposomes.
Maruyama K
Biol Pharm Bull; 2000 Jul; 23(7):791-9. PubMed ID: 10919354
[TBL] [Abstract][Full Text] [Related]
6. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
7. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo.
Ishida O; Maruyama K; Tanahashi H; Iwatsuru M; Sasaki K; Eriguchi M; Yanagie H
Pharm Res; 2001 Jul; 18(7):1042-8. PubMed ID: 11496943
[TBL] [Abstract][Full Text] [Related]
8. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
[TBL] [Abstract][Full Text] [Related]
9. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
10. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
[TBL] [Abstract][Full Text] [Related]
11. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice.
Ishida O; Maruyama K; Sasaki K; Iwatsuru M
Int J Pharm; 1999 Nov; 190(1):49-56. PubMed ID: 10528096
[TBL] [Abstract][Full Text] [Related]
12. Possibility of active targeting to tumor tissues with liposomes.
Maruyama K; Ishida O; Takizawa T; Moribe K
Adv Drug Deliv Rev; 1999 Nov; 40(1-2):89-102. PubMed ID: 10837782
[TBL] [Abstract][Full Text] [Related]
13. A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes.
Shahinian S; Silvius JR
Biochim Biophys Acta; 1995 Nov; 1239(2):157-67. PubMed ID: 7488620
[TBL] [Abstract][Full Text] [Related]
14. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies.
Maruyama K; Takizawa T; Yuda T; Kennel SJ; Huang L; Iwatsuru M
Biochim Biophys Acta; 1995 Mar; 1234(1):74-80. PubMed ID: 7880861
[TBL] [Abstract][Full Text] [Related]
15. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
Sapra P; Moase EH; Ma J; Allen TM
Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
Harding JA; Engbers CM; Newman MS; Goldstein NI; Zalipsky S
Biochim Biophys Acta; 1997 Jul; 1327(2):181-92. PubMed ID: 9271260
[TBL] [Abstract][Full Text] [Related]
17. [PEG-liposome in DDS and clinical studies].
Maruyama K
Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
20. Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells.
Merdan T; Callahan J; Petersen H; Kunath K; Bakowsky U; Kopecková P; Kissel T; Kopecek J
Bioconjug Chem; 2003; 14(5):989-96. PubMed ID: 13129403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
